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Effects of intranasal insulin 
application on the hypothalamic 
BOLD response to glucose 
ingestion
Anna M. van Opstal1, Abimbola A. Akintola2, Marjan van der Elst2, Rudi G. Westendorp2,3, 
Hanno Pijl4, Diana van Heemst2 & Jeroen van der Grond1
The hypothalamus is a crucial structure in the brain that responds to metabolic cues and regulates 
energy homeostasis. Patients with type 2 diabetes demonstrate a lack of hypothalamic neuronal 
response after glucose ingestion, which is suggested to be an underlying cause of the disease. In this 
study, we assessed whether intranasal insulin can be used to enhance neuronal hypothalamic responses 
to glucose ingestion. In a randomized, double-blinded, placebo-controlled 4-double cross-over 
experiment, hypothalamic activation was measured in young non- diabetic subjects by determining 
blood-oxygen-level dependent MRI signals over 30 minutes before and after ingestion of 75 g glucose 
dissolved in 300 ml water, under intranasal insulin or placebo condition. Glucose ingestion under 
placebo condition lead to an average 1.4% hypothalamic BOLD decrease, under insulin condition 
the average response to glucose was a 2.2% decrease. Administration of water did not affect the 
hypothalamic BOLD responses. Intranasal insulin did not change circulating glucose and insulin levels. 
Still, circulating glucose levels showed a significant dampening effect on the BOLD response and insulin 
levels a significant strengthening effect. Our data provide proof of concept for future experiments 
testing the potential of intranasal application of insulin to ameliorate defective homeostatic control in 
patients with type 2 diabetes.
Worldwide, there has been a rapid increase in the number of patients who have type 2 diabetes mellitus. Type 2 
diabetes, found in >90% of all cases of diabetes, is characterized by insulin resistance and a defective secretion 
of insulin. For several decades, glucose homeostasis was assumed to be regulated primarily via peripheral mech-
anisms and centered around insulin produced by pancreatic islet cells and its effects on suppression of hepatic 
glucose production and, stimulation of glucose uptake by adipose tissue and muscle1–3. Recent data however 
demonstrated that the brain also plays a pivotal role in glucose regulation4,5. A key brain area that is involved in 
glucose homeostasis is the hypothalamus, which regulates metabolic homeostasis via its reciprocal projections to 
other brain regions and the periphery6. The hypothalamus senses, integrates and co-ordinates circulating met-
abolic cues, thereby aiding regulation of body weight and feeding behavior6,7. Insulin, a signal reflecting energy 
availability and reserves, provides direct negative feedback to hypothalamic nuclei that control energy and glucose 
homeostasis8. Previous studies have clearly shown that insulin receptors and insulin signaling in the hypothal-
amus is vital in the regulation on glucose and energy metabolism8–11. Studies on the role of the brain in glucose 
regulation in humans have been facilitated by non-invasive techniques such as measurement of blood oxygen 
level dependent (BOLD) brain responses, which allows quantification of brain activities over time during func-
tional MRI studies. BOLD MRI contrast is a reflection of hemodynamic changes associated with neuronal activity 
due to changes in local concentrations of oxygenated and deoxygenated hemoglobin12,13. These BOLD changes 
can be measured in the hypothalamus, in response to glucose or to other stimuli14. In healthy men, a prolonged, 
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dose-dependent decrease in hypothalamic BOLD signal was observed in response to glucose ingestion, showing 
adaptability of the hypothalamus to nutrient ingestion14,15. Conversely, in patients with type 2 diabetes, a lack of 
significant decrease in BOLD signal was observed in response to glucose ingestion, implying diabetes- induced 
failure to inhibit hypothalamic neuronal activity in response to glucose ingestion16. Interestingly, in patients with 
type 2 diabetes, this absent hypothalamic response normalized after a 4-day very-low-calorie diet, indicating that 
hypothalamic dysfunction to glucose sensing is potentially reversible17.
We hypothesize that deficits in central insulin action play a role in defective hypothalamic gluco-regulatory 
responses and that increasing central insulin levels may potentiate brain responses to glucose. Earlier studies 
have shown that insulin, and other compounds, can be non-invasively delivered to the CSF and cross the brain 
barrier via the intranasal route, without spilling over to the periphery, allowing for a specific increase in central 
insulin levels18,19. Several studies have shown that intranasal insulin has an effect on various hypothalamic func-
tions, indicating that the hypothalamus is a target for and is reached by intranasal aplicaition of insulin20,21. In 
a randomized, double blind, placebo-controlled cross-over experiment, we aimed to investigate the hypothesis 
that intranasal insulin application may potentiate the BOLD response to glucose ingestion in the hypothalamus 
in young healthy volunteers. First, we applied insulin or placebo using a customized nasal atomizer. Thereafter 
hypothalamic BOLD signals were measured for 30 minutes before, during and  after ingestion of 75 g glucose 
dissolved in water, or plain water being the control condition.
Results
Subject characteristics. The characteristics of study subjects are summarised in Table 1. The participants 
had a mean age of 22 years and mean BMI of 23.6 kg/m2. The mean fasted glucose was 4.8 mmol/L, median insulin 
level was 0.84 µU/ml and the median HOMA-IR index was 1.2.
Blood glucose and insulin trajectories after intranasal insulin application. The mean serum glu-
cose and insulin trajectories of all participants over 2.5 hour encompassing the time period before, during and 
after the intranasal application of placebo or insulin and MRI scanning procedure are shown in Fig. 1. Serum glu-
cose levels after drinking water were stable throughout the experimental period and were not significantly differ-
ent between insulin and placebo conditions (Fig. 1a). After glucose ingestion, the serum glucose levels increased 
in both intranasal insulin and placebo conditions, with the rise in glucose levels starting approximately 15 min-
utes after glucose ingestion. A peak glucose level of 7.0 mmol/l was reached 50 minutes after glucose ingestion 
under the intranasal insulin condition. For the placebo condition, a peak of 6.3 mmol/l was reached 60 minutes 
after glucose ingestion. Thereafter, glucose levels for both insulin and placebo conditions declined to 5.2 mmol/l 
at the end of the experinment.
Serum insulin levels after drinking water were stable throughout the experimental period and were not signif-
icantly different between the intranasal insulin and placebo conditions (Fig. 1b). After glucose ingestion serum 
insulin levels increased under both intranasal insulin and placebo conditions. After intransal insulin applica-
tion, the serum insulin levels reached a peak of 48.4mU/L at 80 minutes after glucose ingestion. Under intransal 
application of placebo, a peak in serum insulin of 40.65 mU/L was reached 90 minutes after ingesting the glucose 
drink.
Changes in hypothalamic BOLD response. Figure 2 shows the group averaged hypothalamic BOLD 
responses before, during and after ingestion of study stimulus (glucose or water). The water and glucose responses 
under placebo condition are shown in panel a. The corresponding responses under insulin condition are shown 
in panel b.
Over the entire 22- minute post- drinking period, the BOLD response after water ingestion under placebo 
condition, was 0.2% lower compared with baseline, and after glucose ingestion 1.4% lower compared with base-
line. Although the response was lowered after ingestion of glucose compared to water ingestion no significant 
difference between the two conditions was found. Also, no differences between these conditions for the two 
minute time intervals were found.
Panel B shows the water and glucose responses under insulin condition. Over the entire period, the BOLD 
response after water ingestion was 0.1% lower compared with baseline, and after glucose ingestion 2.2% lower 
compared with baseline. For the entire post drink period, the glucose BOLD response was significantly (p = 0.028, 
whole time series mixed-model analysis) lower than the water response. Especially between 20 and 23 minutes 
after ingestion this difference becomes most prominent (p < 0.05 Bonferroni corrected, 2-min window mixed 
model analysis).
Effects of plasma glucose and insulin levels on the BOLD response. Circulating glucose levels 
showed a significant effect on the BOLD response (estimated effect: +0.3% BOLD change, p = 0.001). Indicating 
that a higher plasma glucose level leads to a dampened decrease in the BOLD signal of the hypothalamus. 
Circulating plasma insulin levels had a significant, albeit small, decreasing effect on the BOLD response (esti-
mated effect: −0.03% BOLD change, p = 0.005). The HOMA-IR index did not have a significant effect on the 
BOLD response.
Conclusions
To study the effects of intranasal insulin application on neuronal activity in the hypothalamus after glucose 
ingestion in young healthy volunteers, we performed a randomized, double blind, placebo-controlled cross-over 
proof of concept experiment and applied insulin or placebo via the nose using a customized nasal atomizer. The 
majornew finding of our study is that the decrease in fMRI BOLD response in the hypothalamus after glucose 
ingestionwas augmented after intranasal application of insulin. Furthermore, we found that circulating glucose 
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and insulin levels did not change after intranasal application of insulin compared to placebo indicating that there 
was no spill over to the systemic circulation and we were able to target the CNS specifically. Nevertheless, in line 
with the absence of reduction in hypothalamic BOLD response to glucose previously observed in patients with 
diabetes type 2 with increased circulating glucose16,17, we found that in healthy volunteers higher plasma glucose 
level also lead to reduced hypothalamic BOLD responses.
The hypothalamus plays a key role in the central regulation of food intake and energy metabolism, and specific 
hypothalamic nuclei are critical for the control of peripheral metabolism by insulin6,8. We found intranasal insulin 
administration augmented the decrease in hypothalamic BOLD response to glucose ingestion, with an average 
decrease in the BOLD signal of 1.2% after intranasal placebo applications and 2.2% when the glucose ingestion 
was preceded by intranasal application of insulin. Indicating that central insulin can affect the hypothalamic func-
tion to maintain glucose homeostasis as is suggested by earlier studies8,10,22. Among patients with type 2 diabetes, 
the glucose-induced reduction in hypothalamic BOLD signal was absent, suggesting that glucose ingestion failed 
to inhibit hypothalamic neuronal activity16,17. Considering that we found the decreased BOLD signal to ingested 
glucose was potentiated after intranasal insulin, future experiments might be aimed at testing the potential of 
intranasally applied insulin to rescue the defective BOLD response that was observed in diabetic patients. Future 
studies could also be targeted at performing these experiments under conditions of increased adiposity, such as 
obesity, which has also been implicated to have effects on the hypothalamic response23.
One limitation of this study is that it was done only in male volunteers and it can be speculated that a sex 
dimorphism is present since it is known that there are several sex-specific differences in energy metabolism24. 
This decreases the generalizability of our findings. Another limitation is the indirect measurement of neural activ-
ity in the targeted brain area using BOLD measurement technique, as it is unclear what direct functional conse-
quences these signals reflect without additional measurements of downstream functional effects. Furthermore, 
other pathways could also affect the hypothalamic response to glucose besides the direct sensing of glucose by 
the hypothalamus. Other studies have shown that dopaminergic pathways also respond to energy ingestion and 
could thus have an effect on the hypothalamic response25. To determine this interplay BOLD measurements in the 
limbic system might thus be useful in future studies. The strength of this study is the methodological rigor and the 
fact that the participants were their own controls, thus ruling out possible dilution of effects that could have been 
introduced due to differences in individual phenotypes.
Figure 1. Glucose and insulin trajectories during the experimental period. Concentration of (a) glucose and 
(b) insulin in serum before and after intranasal insulin application (40 IU Insulin actrapid, blue line) or placebo 
(saline, red line) using Vianase nasal atomizer. Data are presented as mean (Standard error) of A. glucose and B. 
insulin levels measured every 10 minutes. The green bar represents the timing of intranasal application, with the 
brown bar represent the timing of ingestion of a glucose drink or water during the fMRI scanning.
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Summarily, using a randomized, double blind, placebo-controlled cross- over proof of concept experiment, 
we studied the effects of intranasal insulin application on blood oxygen level dependent (BOLD) signals as proxy 
for neuronal activity in the key brain area of the hypothalamus that has been implicated in responses to metabolic 
cues. We found that intranasal insulin augmented the decrease in fMRI BOLD signal in response to glucose 
ingestion in the hypothalamus. Further research is needed to investigate whether intranasal application of insulin 
has similar effects on hypothalamic BOLD responses in patients with type 2 diabetes, and what the functional 
consequences are.
Methods
Ethics statement. The study was approved by the Medical Ethical Committee of Leiden University Medical 
Centre under protocol P13.164 and the Dutch competent authority (Centrale Commissie Mensgebonden 
Onderzoek (CCMO)) under protocol code number NL45043.058.13. The study is registered in the European 
Clinical Trials Database under number 2012-005650-29 on the 9th of April 2014. All investigations have been 
conducted according to the principles expressed in the Declaration of Helsinki. All participants provided written 
informed consent after complete written and verbal description of the study was given.
Experimental subjects. Our study population consisted of 8 healthy, normal weight (20 kg/m2 < BMI 
< 25 kg/m2) adult male volunteers from the general population. Exclusion criteria included fasting plasma glu-
cose above 7 mmol/l, anaemia (haemoglobin < 7.1 mmol/l), any significant endocrine, neurological and cardio-
vascular diseases, or use of medication known to influence lipolysis, thyroid function, glucose metabolism, GH/
IGF-1 secretion or any other hormonal axis. Furthermore, persons with a history of smoking addiction, alcohol 
addiction or substance abuse were excluded as well as persons with characteristics that might interfere with 
effective intranasal application, including presence of anatomic deviations of the nose or chronic colds, running 
nose or allergies.
Experimental protocol. We performed a randomized, double-blinded, placebo-controlled cross- over 
experiment. For each participant, the study was carried out on four study visits, each spaced apart by one week. 
The participants were randomized over two treatment arms, with half of the participants having intranasal appli-
cation of placebo first and the other half intranasal application of insulin first. Concealment of treatment alloca-
tion was ensured by delivery of experimental medication in same type of vial that was prepared and re-labelled by 
the hospital pharmacy. De-blinding was done at the end of the study. After a 10 hour overnight fast, participants 
arrived at the MRI facilities at 8AM. First, a baseline venous blood sample was collected in a serum-separator 
(SST)-tube and thereafter, every 10 minutes, 4 ml of blood was collected into a SST-tube and 2 ml into K3-EDTA 
tube. Ten minutes after the first blood withdrawal, the study intervention was applied, which consisted of intrana-
sal application of 40 IU insulin (Actrapid; Novo Nordisk, Mainz, Germany) or placebo (Normal saline), applied 
using the ViaNase Electronic Atomizer (Kurve Technology inc) 20 minutes before the start of the MRI scanning 
procedure. At 30 minutes after application of intranasal insulin/placebo, single slice BOLD mid-brain fMRI scans 
were performed, during which participants drank either the glucose solution or water (75 gr of glucose dissolved 
Figure 2. Hypothalamic BOLD responses under placebo and insulin conditions. Baseline BOLD signal 
measured from minute 1 to 8, ingestion of either glucose solution or water from minute 8 through 11 (indicated 
by grey box), overall response period after ingestion of glucose solution or water from minute 12 through 30. 
Panel a: light blue line: response to water ingestion under placebo condition, orange line: response to glucose 
ingestion under placebo condition. Panel b: dark blue line: response to water ingestion under insulin condition, 
red line: response to glucose ingestion under insulin condition. *Indicates significant differences at p < 0.05 
Bonferroni correct for multiple comparison for separate time window analysis.
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in 300 ml of tap water or 300 ml of plain tap water). This timing of ingestion of the glucose and/or water stimulus 
was chosen as we expected the greatest effect of the intranasal treatment at this time. As previous studies have 
shown that it takes 30 minutes for insulin to reach maximal concentrations in the CSF26, and a similar time 
window has been used previously in other studies where brain – related effects of intranasal insulin were stud-
ied21,27,28. The total time for the BOLD scans (baseline measurement, ingestion and post-ingestion measurements) 
was 30 minutes.
Processing of blood samples. After blood withdrawal, K3-EDTA tubes were immediately placed on ice 
before centrifugation. Serum tubes were kept at room temperature and centrifuged at 3520 RPM at 4 °C for 
10 minutes when the samples were clotted, usually between 30–60 minutes. EDTA plasma and serum samples 
were stored in two aliquots of 500 µl during the rest of the study day at −20 °C. After completion of sample collec-
tion, these were stored at −80 °C. All laboratory measurements were performed with fully automated equipment 
and diagnostics from Roche Diagnostics (Almere, The Netherlands). Glucose levels were measured using Hitachi 
Modular P800 from Roche (Almere, the Netherlands), with coefficient of variation (CV) for measurement less 
than 1%. Insulin levels were measured using the Immulite 2500 from DPC (Los Angeles, CA), with CV less than 
6%. HOMA-IR index was calculated according to the formula: fasting insulin × fasting glucose/22.5.
MRI acquisition and analysis. MRI was performed on a 3.0 Tesla clinical MRI scanner (Achieva Philips 
Healthcare, Best, the Netherlands). We performed a structural mid brain T1 scan (single slice scan, repetition 
time 550 ms, echo time 10 ms, field of view 208 × 208 mm, voxel size = 0.52 × 0.52 × 14 mm, scan time 1.14 min) 
and a high resolution mid brain single slice fMRI scan (repetition time 120 ms, echo time 30 ms, field of view 
208 × 208 mm, voxel size = 0.81 × 0.81 × 14 mm, scan time 30 min, 700 dynamic volumes). Both of these single 
slice mid-sagittal scans were planned using third ventricle, the corpus callosum and brain midline as landmarks. 
Data was pre-processed as described in previous studies17. Data was averaged for each set of 4 subsequent vol-
umes, reducing the 700 dynamic scans to 175. The hypothalamus was segmented manually, using the mid brain 
Figure 3. Segementation of the hypothalamus region of interest (ROI). For the hypothalamus ROI (A), the 
optic chiasm (1), the mammillary bodies (2), the thalamus (3) the anterior commissure (4) and the top of the 
cerebral aqueduct (5) were used as landmarks. The reference ROI was drawn superior of the genu to the corpus 
callosum (6) in the grey matter.
Characteristics
Demographics N = 8
Age in years (SD) 22.3 (1.8)
BMI in kg/m2 23.6 (2.2)
Alcohol intake (units/week) 14.4 (2.2)
Systolic BP (mmHg) 125 (9.3)
Diastolic BP (mmHg) 74 (7.2)
Metabolic
Fasted glucose in mmol/L 4.8 (0.3)
Fasted insulin in µU/ml, median (IQR) 0.84 (0.69, 0.95)
HOMA-IR index, median (IQR) 1.2 (1.0, 1.5)
Table 1. Characteristics of study subjects. Unless otherwise stated, values are means (standard deviation). BMI: 
body mass index.
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single slice anatomical image as a guide for delineation. Manual segmentation was performed on the middle 
dynamic volume of the fMRI scan as described previously using the anterior commissure, the optic chiasm and 
the mammillary bodies as anatomical landmarks14,17. Example delineation of the hypothalamus, with the anatom-
ical landmarks used for delineation, is shown in Fig. 3. To correct for scanner drift, all hypothalamic BOLD values 
were corrected using an internal reference ROI in the grey matter superior of the genu of the corpus callosum.
Statistical Analysis. For statistical analyses, Statistical Package for Social Sciences (SPSS) software for 
windows (version 22.0) was used. Graphs were made using GraphPad Prism version 5 (GraphPad, San Diego, 
CA). Descriptive statistics were used to summarise the characteristics of both study groups. All fMRI results 
are reported as percentage BOLD change, relative to baseline; 0–8 minute BOLD response before drinking of 
the test solution. For presentation purposes, the individual 175 dynamic scans time points were pooled into ‘per 
minute’ data points: The first 8 minutes were considered baseline BOLD response. Data from minute 8 through 
11 were omitted from the analysis due to non-physiologic excessive BOLD changes caused by swallowing of the 
drink. Statistical analysis of the differences in effect between the study stimuli on the overall BOLD response 
was performed by a single linear mixed model analysis using the study stimulus as a fixed effect, time point as a 
covariate and subject per occasion as a random factor using the total time series. Differences in treatment effect 
was deemed significant at p < 0.05. To test for treatment effects over time the same model was used per two min-
ute intervals instead of the entire series. P-values for the analysis per two minute intervals are reported corrected 
for multiple comparison with a Bonferonni correction of eight (p < 0.00625). To test for the influence of blood 
glucose and insulin levels and the HOMA-IR index on the response to the study stimuli, additional mixed model 
analyses were performed, in which these values were added as covariates. These effects of glucose and insulin on 
the BOLD response are reported as estimated effects in percentage BOLD change.
Data availability. The datasets generated during and/or analysed during the current study are available from 
the corresponding author on reasonable request.
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